Journal
JOURNAL OF CLINICAL GASTROENTEROLOGY
Volume 52, Issue 7, Pages 641-647Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MCG.0000000000000857
Keywords
direct-acting antivirals; hepatitis C; treatment uptake; chronic hepatitis cohort study
Categories
Funding
- Centers for Disease Control and Prevention
- Gilead Sciences
- CDC Foundation
- AbbVie
- Genentech
- A Member of the Roche Group
- Janssen Pharmaceuticals, Inc.
- Vertex Pharmaceuticals
- Bristol-Myers Squibb
- AbbVie Pharmaceuticals
- Conatus
- CymaBay
- Exalenz BioScience
- Gilead Pharmaceuticals
- Intercept Pharmaceuticals
- Merck
- National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) [U18PS005154] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Background:Limited information is available describing the uptake of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection among patients in general US health care settings. We determined the proportion of HCV-infected patients in the Chronic Hepatitis Cohort Study prescribed DAAs in 2014, who initiated treatment and identified characteristics associated with treatment initiation.Methods:Uptake was defined as the proportion of HCV-infected patients with at least 1 clinical encounter in 2013 who were prescribed a DAA regimen during 2014 and initiated the regimen by August 2015. Using multivariable analysis, we examined demographic and clinical characteristics associated with receipt of DAAs.Results:The cohort comprised 9508 patients; 544 (5.7%) started a DAA regimen. Higher annual income [adjusted odds ratios (aOR) 2.3 for income>$50K vs. <$30K], higher Fibrosis-4 score (aORs, 2.1, 2.0, and 1.4 for Fibrosis-4, >5.88, 3.25 to 5.88, 2.0 to 3.25, respectively, vs. <2.0), genotype 2 infection (aOR 2.2 vs. genotype 1), pre-2014 treatment failure (aOR 2.0 vs. treatment-naive), and human immunodeficiency virus (HIV) coinfection (aOR 1.8 vs. HCV monoinfection) were associated with DAA initiation. Black race/ethnicity (aOR 0.7 vs. whites) and Medicaid coverage (aOR 0.5 vs. private insurance) were associated with noninitiation. Sex, age, comorbidity, previous liver transplant, and duration of follow-up were not associated with receipt of DAAs.Conclusions:Among patients in these general US health care settings, uptake of DAA therapy was low in 2014, and especially so among minority and Medicaid patients. Systemic efforts to improve access to DAAs for all patients are essential to reduce morbidity and mortality from HCV infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available